Harvard Bioscience Approves Incentive Plan Amendment

Harvard Bioscience ( (HBIO) ) has issued an update.

On May 30, 2025, Thomas Loewald resigned from the board of directors of Harvard Bioscience, Inc., with no disagreements related to company operations. On June 2, 2025, the company’s stockholders approved an amendment to the 2021 Incentive Plan, increasing the number of authorized shares by 3,923,000. John D. Duke was appointed to the board and as a member of the Audit and Nominating and Governance Committees, while Katherine Eade was named Lead Independent Director. The company held its 2025 Annual Meeting of Stockholders, where several proposals were voted on, including the election of a director and the ratification of Grant Thornton LLP as the independent accounting firm.

The most recent analyst rating on (HBIO) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.

Spark’s Take on HBIO Stock

According to Spark, TipRanks’ AI Analyst, HBIO is a Neutral.

The overall stock score reflects significant financial and operational challenges, compounded by negative technical signals and valuation concerns. The earnings call provides some optimism with product innovations and market opportunities, but recent corporate events and compliance issues add risks.

To see Spark’s full report on HBIO stock, click here.

More about Harvard Bioscience

Harvard Bioscience, Inc. is a leading developer, manufacturer, and seller of technologies, products, and services that advance life science applications, including research, drug and therapy discovery, bio-production, and preclinical testing for pharmaceutical and therapy development. The company serves a diverse customer base, including academic institutions, government laboratories, and leading pharmaceutical, biotechnology, and contract research organizations, with operations in the United States, Europe, and China.

Average Trading Volume: 10,900,140

Technical Sentiment Signal: Sell

Current Market Cap: $20.65M

Learn more about HBIO stock on TipRanks’ Stock Analysis page.